<DOC>
	<DOC>NCT00898560</DOC>
	<brief_summary>The purpose of this study is to investigate whether multiple-dose administration of eslicarbazepine acetate (ESL, BIA 2-093) 800 mg once-daily (QD) affects the pharmacokinetics and tolerability of the components of a combined oral contraceptive (ethinyloestradiol and levonorgestrel).</brief_summary>
	<brief_title>Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies, Partial</mesh_term>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives, Oral, Combined</mesh_term>
	<criteria>Premenopausal female subjects Age 1840 years, inclusive Body mass index (BMI) 1930 kg/m2, inclusive Healthy as determined by prestudy medical history, physical examination, vital signs, complete neurological examination and 12lead ECG Negative tests for HBsAg, antiHCVAb and HIV1 and HIV2 Ab at screening Negative urine pregnancy test at screening and admission to each treatment period. Using one of the following methods of contraception: double barrier or intrauterine device Subjects who have any contraindication to the use of oral contraceptives History or presence of clinically relevant diseases, disorders or surgical history History of alcoholism or drug abuse Have used medicines within two weeks of admission to first period that may affect the safety or other study assessments, in the investigator's opinion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Partial</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Eslicarbazepine acetate</keyword>
	<keyword>Combined oral contraceptive</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Tolerability</keyword>
</DOC>